Copanlisib is an intravenous pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against both PI3K-d and PI3K-a isoforms. The program now includes two new Phase III trials
Gencarois, the company’s investigational, pharmacologically unique beta-blocker and mild vasodilator, is indicated for heart failure patients with reduced left ventricular ejection fraction (HFREF). Currently, Gencaro is being evaluated
As part of the deal, Boehringer is responsible for the global development and commercialization of the new inhibitors, while Hydra will receive an undisclosed upfront payment, additional research
IV/IM meloxicam is a proprietary, Phase III-ready, long-acting COX-2 NSAID designed for the management of moderate to severe acute pain. As part of the deal, Recro paid Alkermes
In February 2015, the US Food and Drug Administration (FDA) granted approval for Liletta based on the largest hormonal IUD trial conducted in the US, A Comprehensive Contraceptive
Under the five-year deal, AstraZeneca will have access to PatientsLikeMe’s global network in support of its patient-driven research initiatives. AstraZeneca Global Medicines Development EVP Briggs Morrison said: "Understanding
In the multicenter, randomized, double-blind, placebo-controlled, multi-dose trial (Heparc-2004), ARC-520 will be administered intravenously to patients with chronic immune active HBV infection maintained on entecavir or tenofovir therapy.
Both the parties will conduct a two-year research program for the development of small molecules targeting the cell surface protein ADAM8, which has been linked to tumor survival,
PAH is a life-threatening disease involving endothelial dysfunction, pulmonary vasoconstriction, vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. In addition, PAH involves skeletal muscle dysfunction that contributes to
The company said that IND remains on partial clinical hold with regard to doses above 0.24 mg/kg/day in healthy volunteers. The randomized, single-blind, placebo-controlled TKM-Ebola Phase I clinical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.